Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677300 · ClinicalTrials.gov registry record · Phase 4
Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients
A Phase 4 study, sponsored by Dallas VA Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 85
- Enrollment target
NCT00677300 is a Phase 4 study that has completed, run by Dallas VA Medical Center. The registered enrollment target is 85 participants.
The verdict
NCT00677300, a Phase 4 study, has completed, sponsored by Dallas VA Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a combination of raltegravir and darunavir is as effective as standard regimens in the treatment of HIV-infected patients who have not previously used antiretroviral drug (treatment naive)
Interventions
- DRUG Ritonavir
- DRUG Raltegravir
- DRUG Darunavir
- DRUG Tenofovir/Emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677300
The ClinicalTrials.gov registry entry for NCT00677300 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dallas VA Medical Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.
NCT00677300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00677300 about?
NCT00677300 is a clinical study titled "Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients". The purpose of this study is to determine whether a combination of raltegravir and darunavir is as effective as standard regimens in the treatment of HIV-infected patients who have not previously used antiretroviral drug (treatment naive)
What is the current status of trial NCT00677300?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 85 participants. The study started on 2009-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00677300?
The interventions under investigation include: Ritonavir (DRUG), Raltegravir (DRUG), Darunavir (DRUG), Tenofovir/Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT00677300?
This trial is sponsored by Dallas VA Medical Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.